A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy

Devarasetti, Phani Kumar; Rajasekhar, Liza; Baisya, Ritasman; Sreejitha, K. S.; Vardhan, Yerram Keerthi

doi:10.1007/s12026-020-09169-x

Cited by 19 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neutralizing antibodies specific to the RBD of SARS-CoV-2 have been discovered in both mice and humans 149,150 , and passive transfer of these antibodies reduces disease severity and offers protection in mouse models of SARS-CoV-2. Convalescent patient serum samples have also yielded promising results in the clinic 151 . However, the natural role that antibodies play during the course of COVID-19 progression remains contested.…”

Section: B Lymphocytesmentioning

confidence: 99%

SARS-CoV-2, COVID-19 and the aging immune system

et al. 2021

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic is a global health threat with particular risk for severe disease and death in older adults and in adults with age-related metabolic and cardiovascular disease. Recent advances in the science of aging have highlighted how aging pathways control not only lifespan but also healthspan -the healthy years of life. Here, we discuss the aging immune system and its ability to respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We specifically focus on the intersect of severe COVID-19 and immunosenescence to highlight pathways that may be determinant for the risk of complications and death following infection with SARS-CoV-2. New or adapted therapeutics that target agingassociated pathways may be important tools to reduce the burden of death and long-term disability caused by this pandemic. Proposed interventions aimed at immunosenescence could enhance immune function not only in older adults but in susceptible younger individuals as well, ultimately improving complications of severe COVID-19 for all ages.

show abstract

Section: B Lymphocytesmentioning

confidence: 99%

SARS-CoV-2, COVID-19 and the aging immune system

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Similarly, the combination of two recombinant human monoclonal antibodies, casirivimab, and imdevimab, was reported for use in the treatment of COVID-19 [41]. Convalescent plasma (CP), obtained from plasma derived from healthy donors recovered from COVID-19, contains virus-specific antibodies that could provide passive immunity in infected patients [42]. Despite the current standard therapy for COVID-19, new drugs should continue to be investigated as, the long-term effects of drugs and vaccines will be revealed in several years.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Potential Drugs Against COVID-19 Revealed By Gene Expression profile, Molecular Docking and Molecular Dynamic Simulation

2021

View full text Add to dashboard Cite

Aim: SARS-CoV-2, an emerging betacoronavirus, is the causative agent of COVID-19. Currently, there are few specific and selective antiviral drugs for the treatment and vaccines to prevent contagion. However, their long-term effects can be revealed after several years, and new drugs for COVID-19 should continue to be investigated. Materials & methods: In the first step of our study we identified, through a gene expression analysis, several drugs that could act on the biological pathways altered in COVID-19. In the second step, we performed a docking simulation to test the properties of the identified drugs to target SARS-CoV-2. Results: The drugs that showed a higher binding affinity are bardoxolone (-8.78 kcal/mol), irinotecan (-8.40 kcal/mol) and pyrotinib (-8.40 kcal/mol). Conclusion: We suggested some drugs that could be efficient in treating COVID-19.

show abstract

“…Several studies, including randomized controlled trials (RCTs) as well as observational studies, showed favorable trends in terms of viral load, oxygen demand, progression to intensive care, recovery time, and/or death. (31)(32)(33) Mechanistically, besides the obvious effect of antibodies, the reversals in disease severity could be attributed to a transient reduction in detrimental cytokines and changes in lymphocyte subpopulations. (34) However, plasma therapy could not attain the status of standard care owing to its application based on the clinician's judgment of risk versus benefit to individual patients, lack of sufficient data from RCTs, and uncertainties about its efficacy.…”

Section: Serum/plasma Therapymentioning

confidence: 99%

Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond

Kumar

Gauthami

Bayry

et al. 2021

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

View full text Add to dashboard Cite

The dawn of the 20th century saw the formative years of developments in immunology. In particular, immunochemistry, specifically pertaining to antibodies, was extensively studied. These studies laid the foundations for employing antibodies in a variety of ways. Not surprisingly, antibodies have been used for applications ranging from biomedical research to disease diagnostics and therapeutics to evaluation of immune responses during natural infection and those elicited by vaccines. Despite recent advancements in cellular immunology and the excitement of T cell therapy, use of antibodies represents a large proportion of immunotherapeutic approaches as well as clinical interventions. Polyclonal antibodies in the form of plasma or sera continue to be used to treat a number of diseases, including autoimmune disorders, cancers, and infectious diseases. Historically, antisera to toxins have been the longest serving biotherapeutics. In addition, intravenous immunoglobulins (IVIg) have been extensively used to treat not only immunodeficiency conditions but also autoimmune disorders. Beyond the simplistic suppositions of their action, the IVIg have also unraveled the immune regulatory and homeostatic ramifications of their use. The advent of monoclonal antibodies (MAbs), on the other hand, has provided a clear pathway for their development as drug molecules. MAbs have found a clear place in the treatment of cancers and extending lives and have been used in a variety of other conditions. In this review, we capture the important developments in the therapeutic applications of antibodies to alleviate disease, with a focus on some of the recent developments.

show abstract

A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy

Cited by 19 publications

References 35 publications

SARS-CoV-2, COVID-19 and the aging immune system

SARS-CoV-2, COVID-19 and the aging immune system

Potential Drugs Against COVID-19 Revealed By Gene Expression profile, Molecular Docking and Molecular Dynamic Simulation

Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond

Contact Info

Product

Resources

About